IBIO - iBio, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

IBIO

IBIO, INC.

NASDAQ

$1.13

▲ UP 0.44% (0.01)

KEY STATISTICS

Market Cap$72.35 M

52w High$3.82

52w Low$0.78

Dividend Yield—

Frequency—

P/E-3.65

Volume349.43K

Shares Out.64.31M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Martin Brenner

COMPENSATION 2026

Salary$580,000

Stock Awards$0

Incentive Plan Pay$319,000

All Other Comp.$13,680

Total$2,136,934

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 19, 2008

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

PRICE TARGET

Target High$5.00

Target Low$5.00

Target Median$5.00

Target Consensus$5.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$20.00K

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2023-11-29	Reverse	1:20
2022-10-10	Reverse	1:25
2018-06-11	Reverse	1:10

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

21.69%

HOLDERS

TOP 8 OF 72 · RANKED BY POSITION SIZE

Affinity Asset Advisors, LLC

Logos Global Management LP

2.0M sh

$3.86M

Frazier Life Sciences Management, L.P.

2.0M sh

$3.77M

Millennium Management LLC

1.5M sh

$2.94M

Balyasny Asset Management L.P.

1.1M sh

$2.12M

Lynx1 Capital Management LP

PRICE

$1.13 ▲ UP 0.44% (+$0.01)

OVERLAYS

About iBio, Inc.

https://www.ibioinc.com ↗

iBio, Inc. is a Texas-based biotech firm offering contract development, manufacturing, and development of therapeutics and vaccines, including candidates for scleroderma, pulmonary fibrosis, COVID-19, and other diseases.

INDUSTRY

Biotechnology

A PRODUCT IBIO, INC. IS KNOWN FOR

IBIO-600

IBIO-600 is a long-acting monoclonal antibody targeting myostatin to preserve muscle mass in obesity, with Phase 1a trials planned for early 2026.

COMPETITORS

COMPETITOR

iBio in 2025

SENTIMENT: + POSITIVE

INNOVATION · DECEMBER 2025

iBio Stock Surges 40% on Promising Developments in AI-Driven Obesity Drug Pipeline

In late 2025, iBio captured significant investor and media attention following a series of positive announcements related to its AI-driven precision antibody therapies for obesity, particularly the compelling preclinical data for its lead candidate, IBIO-610. This culminated in a 40% surge in the company's stock price on a single day in early December, highlighting strong market enthusiasm for its innovative approach to developing next-generation treatments for cardiometabolic diseases.

TECHNOLOGY · FISCAL YEAR 2025 (ENDING JUNE 30, 2025) · IN PROGRESS

iBio Pivots to AI-Driven Antibody Platform Targeting High-Growth Obesity and Cardiometabolic Markets

In 2025, iBio executed a transformative strategic shift, repositioning itself as an AI-driven innovator of precision antibody therapies. This intentional pivot centers on developing a pipeline of next-generation treatments for obesity and cardiometabolic diseases, moving away from a broader focus to a specialized, technology-led approach with key preclinical assets like IBIO-610 and IBIO-600. [2, 9]